180 related articles for article (PubMed ID: 37433122)
1. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids.
Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122
[No Abstract] [Full Text] [Related]
2. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era.
Amram O; Amiri S; Panwala V; Lutz R; Joudrey PJ; Socias E
Am J Drug Alcohol Abuse; 2021 Nov; 47(6):722-729. PubMed ID: 34670453
[TBL] [Abstract][Full Text] [Related]
3. COVID-19-related flexibility in methadone take-home doses associated with decreased attrition: Report from an opioid treatment program in central Pennsylvania.
Kawasaki SS; Zimmerman R; Shen C; Zgierska AE
J Subst Use Addict Treat; 2023 Dec; 155():209164. PubMed ID: 37730014
[TBL] [Abstract][Full Text] [Related]
4. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
[TBL] [Abstract][Full Text] [Related]
5. Changes in methadone take-home dosing before and after COVID-19.
Amram O; Amiri S; Thorn EL; Lutz R; Joudrey PJ
J Subst Abuse Treat; 2022 Feb; 133():108552. PubMed ID: 34304950
[TBL] [Abstract][Full Text] [Related]
6. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
7. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Brothers S; Viera A; Heimer R
J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
[TBL] [Abstract][Full Text] [Related]
8. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
[TBL] [Abstract][Full Text] [Related]
9. Opioids for cancer pain - an overview of Cochrane reviews.
Wiffen PJ; Wee B; Derry S; Bell RF; Moore RA
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012592. PubMed ID: 28683172
[TBL] [Abstract][Full Text] [Related]
10. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
[TBL] [Abstract][Full Text] [Related]
11. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19.
Figgatt MC; Salazar Z; Day E; Vincent L; Dasgupta N
J Subst Abuse Treat; 2021 Apr; 123():108276. PubMed ID: 33612201
[TBL] [Abstract][Full Text] [Related]
12. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
Roy V; Buonora M; Simon C; Dooling B; Joudrey P
Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861
[TBL] [Abstract][Full Text] [Related]
13. Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year.
Bart G; Wastvedt S; Hodges JS; Rosenthal R
J Subst Abuse Treat; 2022 Feb; 133():108590. PubMed ID: 34373169
[TBL] [Abstract][Full Text] [Related]
14. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
Bortz C; Armistead I; Bonaguidi A; Coyle DT
J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
[TBL] [Abstract][Full Text] [Related]
15. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
[TBL] [Abstract][Full Text] [Related]
16. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
17. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
[TBL] [Abstract][Full Text] [Related]
18. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.
Dunn KE; Brooner RK; Stoller KB
J Subst Abuse Treat; 2021 Feb; 121():108197. PubMed ID: 33357606
[TBL] [Abstract][Full Text] [Related]
19. Adapting methadone inductions to the fentanyl era.
Buresh M; Nahvi S; Steiger S; Weinstein ZM
J Subst Abuse Treat; 2022 Oct; 141():108832. PubMed ID: 35870437
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]